A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia

2013 ◽  
pp. n/a-n/a ◽  
Author(s):  
Carsten Müller-Tidow ◽  
Gesine Bug ◽  
Michael Lübbert ◽  
Alwin Krämer ◽  
Jürgen Krauter ◽  
...  
The Lancet ◽  
2012 ◽  
Vol 379 (9825) ◽  
pp. 1508-1516 ◽  
Author(s):  
Sylvie Castaigne ◽  
Cécile Pautas ◽  
Christine Terré ◽  
Emmanuel Raffoux ◽  
Dominique Bordessoule ◽  
...  

2018 ◽  
Vol 185 (3) ◽  
pp. 583-587
Author(s):  
Hartmut Döhner ◽  
Carsten Müller‐Tidow ◽  
Michael Lübbert ◽  
Walter Fiedler ◽  
Alwin Krämer ◽  
...  

2017 ◽  
Vol 18 (8) ◽  
pp. 1061-1075 ◽  
Author(s):  
Alexander E Perl ◽  
Jessica K Altman ◽  
Jorge Cortes ◽  
Catherine Smith ◽  
Mark Litzow ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document